The 15-year OS rate was 60% among prostate brachytherapy recipients and 55% among EBRT recipients, indicating no significant difference between the arms. In prostate cancer, prostate brachytherapy (PB ...

A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...

Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

Becker’s ASC Review sat down with Randy Whaley, director of business development for United Medical Systems, to tackle a reader’s question about what is needed for an ASC to be able to offer and ...

Rates of acute GI and GU toxicities with dose-escalated intensity modulated proton therapy (IMPT) for the treatment of node-positive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ...